Cardiogenic shock is characterized by tissue hypoxia caused by circulatory failure arising
from inadequate cardiac output. In addition to treating the pathologic process causing …

Review of the current literature fails to show significant mortality benefit with any specific
vasopressor or inotropic in CS patients. The upcoming DOREMI 2 and levosimendan versus …

Background Recent studies have shown improved outcomes in cardiogenic shock through
protocols directed toward early identification and initiation of mechanical circulatory support …

Purpose To compare the relative efficacy of supportive therapies (inotropes, vasopressors,
and mechanical circulatory support [MCS]) for adult patients with cardiogenic shock …

Background Cardiogenic shock (CS) is a state of end-organ hypoperfusion related to
cardiac dysfunction. Current guidelines recommend consideration of inotrope therapy in …

Background Cardiogenic shock remains highly associated with early mortality, with mortality
often exceeding 50%. We sought to determine the association between prognostic factors …

TEER remains a promising therapeutic option in cardiogenic shock complicated by
significant mitral regurgitation, but additional research is required to identify patient and …

Aims Studies in cardiogenic shock (CS) often have a heterogeneous population of patients,
including those with acute myocardial infarction and acute decompensated heart failure …

OBJECTIVES: Inotropic support is commonly used in patients with cardiogenic shock (CS).
High-quality data guiding the use of dobutamine or milrinone among this patient population …

Background Cardiogenic shock due to acute myocardial infarction (AMI-CS) is associated
with significant short-and long-term morbidity and mortality. Despite this, little is known about …